WSJ Tech News Briefing – TNB Tech Minute: Gilead Sciences to Buy Biotech Arcellx
Date: February 23, 2026
Host: Julie Chang (The Wall Street Journal)
Episode Overview
This episode of the WSJ Tech News Briefing delivers a concise roundup of significant technology and business stories for Monday, February 23rd. The main highlights include Gilead Sciences' acquisition of its biotech partner Arcellx, major movements in the electric vehicle joint venture Flexus, and Nvidia's return to the consumer PC market with new AI-powered chips.
Key Discussion Points and Insights
1. Gilead Sciences to Acquire Arcellx
[00:31–01:14]
- Deal Details: Gilead Sciences agreed to purchase the remaining stake in Arcellx, a development partner in biotech, in a transaction valuing Arcellx at approximately $7.8 billion.
- Purchase Terms: $115 per share in cash for the 88.5% of Arcellx it doesn't already own—a 79% premium to Arcellx's previous closing price.
- Background: The companies have been partners since 2022, co-developing and commercializing Annidocell, an investigational CAR T-cell therapy for multiple myeloma (a type of blood cancer).
- Strategic Significance: The move gives Gilead full control over Annidocell and is part of Gilead's effort to strengthen its blood cancer treatment portfolio.
- Timeline: The acquisition is expected to close in the second quarter of 2026.
Julie Chang [00:33]: "Gilead Sciences has agreed to buy the rest of development partner Arcellx in a deal that values the biotech company at about $7.8 billion... a 79% premium to Friday's closing price."
2. Renault to Acquire Full Ownership of Flexus JV
[01:14–01:42]
- Transaction Overview: Renault will acquire Volvo Group's and CMA CGM's remaining shares in Flexus, which specializes in electric vans.
- Background: The joint venture Flexus was established by Renault, Volvo, and CMA CGM in 2024.
- Renault's Plans: With full ownership, Renault will continue developing fully electric light commercial vehicles under the Flexus project.
- Next Steps: The agreement is pending regulatory approval.
Julie Chang [01:18]: "Renault said it would acquire Volvo Group's and CMA CGM's remaining stake in electric Van Flexus... The French carmaker said it'll take full ownership of Flexus and carry the project through completion..."
3. Nvidia’s New AI Laptop Chips
[01:42–02:05]
- Product Launch: Nvidia’s chips for laptop computers are set to launch this year, featured in products from Dell, Lenovo, and others.
- Strategic Move: Marks Nvidia’s return to the consumer PC market, with a focus on leading the hardware component of the AI revolution.
- Industry Context: The company is working with both Intel and Mediatek (a major Taiwanese chip designer) to bring these innovations to market.
- Analyst Insight: Nvidia aims to maintain a connection with consumers as AI becomes integral to every device.
Julie Chang [01:48]: “The move marks a return to the consumer PC market for the leader in AI chips. Analysts say Nvidia wants to keep connection with consumers in an era where every device will be AI enabled.”
Memorable Quotes & Moments
-
On the Gilead-Arcellx Deal
"Biopharmaceutical company Gilead and Arcellx struck a deal in 2022 to co develop and co commercialize Annidocell, an investigational CAR T cell therapy for patients with the blood cancer multiple myeloma."
– Julie Chang [00:44] -
On the EV Market
"The agreement still needs regulatory approval, and Nvidia chips for laptop computers are set to hit the market this year in products from Dell, Lenovo and others."
– Julie Chang [01:37]
Timestamps for Major Stories
- Gilead Sciences—Arcellx acquisition: 00:31–01:14
- Renault—Flexus JV acquisition: 01:14–01:42
- Nvidia AI laptop chips: 01:42–02:05
Summary
This Tech Minute edition spotlights high-impact developments across biotech, automotive, and semiconductor sectors. Gilead’s $7.8 billion deal grants it full control over a promising cancer therapy. Renault consolidates its position in the electric van market, and Nvidia doubles down on AI-powered computing for everyday users. These moves underscore accelerating innovation and realignment in key technology sectors.